Wayne Woo, MD
Endocrinology, Diabetes & Metabolism · Flowood, MSNPI 1023064177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 1,402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 1,402 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Novo Nordisk$4K
- Tandem Diabetes Care, Inc.$3K
- Amgen$2K
- Lilly USA, LLC$2K
- AstraZeneca$2K
- plus $13K from 46 others
What the payments were for
- Speaking & faculty fees$2,4008%
- Food & beverage$27,25390%
- Education$4642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$1,300
- t:slim X2 insulin pump$1,100
- FREESTYLE LIBRE 3$588
- FARXIGA$448
- iLet Bionic Pancreas$375
- FreeStyle Libre$343
- FreeStyle Freedom Lite system$336
- Vascepa$250
- EVENITY$230
- Ozempic$226
- FreeStyle Libre 2$212
- Tymlos$125
- iLet Insulin Infusion Kit Inset$125
- iLet Insulin Infusion Kit Contact Detach$125
- ZENPEP$124
- Repatha$119
- RYBELSUS$117
- DEXCOM G6 TRANSMITTER$112
- Prolia$107
- JARDIANCE$104
How this compares
$30,117 in reported general payments places this provider in the 75th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 612 | $798,046 |
| JardianceEmpagliflozin | 382 | $328,546 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 305 | $243,579 |
| FarxigaDapagliflozin Propanediol | 205 | $169,616 |
| TrulicityDulaglutide | 118 | $144,150 |
| MounjaroTirzepatide | 108 | $130,642 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 76 | $90,702 |
| TradjentaLinagliptin | 140 | $87,484 |
| Tresiba Flextouch U-100Insulin Degludec | 153 | $74,720 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 114 | $73,947 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $67,947 |
| KerendiaFinerenone | 61 | $66,723 |
| Xigduo XrDapaglifloz Propaned/Metformin | 82 | $58,903 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $49,191 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 65 | $45,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $3,678 | $923,438747 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy, Glyxambi | $1,326 | $519,446649 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $2,182 | $274,792226 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,119 | $243,579305 claims |
| AstraZenecaFarxiga | $1,922 | $169,616205 claims |
| MerckJanumet Xr, Januvia, Janumet | $919 | $116,417170 claims |
| BayerKerendia | $1,173 | $66,72361 claims |
| AbbVieSynthroid | $932 | $43,681688 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $198 | $9,76518 claims |
| Amneal Pharmaceuticals LLCUnithroid | $202 | $7,34499 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Flowood
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- John SistrunkJackson$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.